Cheap-to-serve incremental business: management says the next tranche of volume costs it almost nothing extra
The model's full reasoning — Q2 2023 call → NOWe need to determine if management conveys that the cost of serving the next increment of business is unusually low because they have already built and paid for resources, and that additional business of that kind is already arriving now. Let's analyze the transcript. Key points from management: - Strong financial results, revenue growth, EBITDA growth. - They have multiple growth drivers: KEDRAB sales, Kedrion distribution, FDA-approved immunoglobulins, Israeli distribution. - They reiterate full year guidance. - They mention a $60 million financing from FIMI, which will provide financial flexibility for business development. - KEDRAB: They mention increased demand, significant increase in sales to Kedrion, and they expect further momentum. They also mention that Kedrion extended distribution agreement through 2026. They are in active discussions to expand collaboration. - They have a U.S. team established in 2022 that is promoting specialty immunoglobulins. They say "our U.S. team established during 2022 continues to achieve good progress in promoting our specialty immunoglobulin portfolio." This suggests the team is already in place. - They mention FDA approval to manufacture CYTOGAM at their Israeli facility, and Health Canada approval, ensuring continued supply. They expect to initiate sales of product manufactured in Israeli facility early Q4. - They have a plasma collection center in Beaumont, Texas, and are expanding capacity, and opening a second center in Houston in early 2024. That suggests they are building more capacity, not just using existing. - On development, InnovAATe trial enrollment is ramping, 62 patients enrolled, about 30% of required. They received positive scientific advice from EMA confirming design. They plan to discuss with FDA by end of year. - They mention that they expect enhanced profitability in second half of year as compared to first half. Now, does management convey that the next unit of business is cheap to serve? They talk about having a U.S. team already established, and that they are promoting products. They also have manufacturing approvals that allow them to supply products. But do they explicitly say that incremental business does not require proportional spending? They mention that they expect operating expenses to increase 15-20% in 2023 as they invest in commercial activities and the Phase III trial.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| HFWA | Heritage Financial Corporation | Q4 2021 | 2022-01-27 | A |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| ESRT | Empire State Realty Trust, Inc. | Q2 2021 | 2021-07-29 | C+ |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
SATS · Q1 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...NO The transcript shows management describing high growth with significant upfront acquisition costs, fixed costs leading to margin expansion as growth slows, and beams filling up faster than expected on Jupiter-2 (implying approaching capacity limits rather than excess capacity). However, there is no clear indication of an already-built, underutilized base where additional business is arriving on resources already paid for without new capacity investment. Instead, they highlight ongoing build-out (Jupiter-3 in 2021) and potential slowdowns, which aligns with the "NO" criteria for being near limits or in a growth cycle requiring new spending.
ATI · Q1 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...YES Management describes the HPMC segment’s leverage from “additional volume across our asset base” and “utilization increases across our isothermal and conventional forging assets” that already generated “significant incremental margin growth,” with next-generation jet engine sales up 65% and now at 48% of total jet engine sales. They state they are “well positioned both in capability and capacity to continue to benefit from these trends well into the future” after noting the fourth press is coming on stream in a couple of years.
UMH · Q3 2018 → YESThe question is about whether management conveys that the cost of serving the next increment of business has become unusually low, meaning additional volume can be delivered with already built and pai...YES The transcript shows management conveying exactly this situation: the company already owns 3,600 vacant sites (most acquired) plus 6,215 rental homes (93.3% occupied), so the next increment of rental-home business can be served on infrastructure already paid for and in place. They explicitly call the rental program “the most efficient way to fill the vacant sites,” and they are already adding 608 homes this year on track for 800, with Same-Property occupancy rising to 83.2% and expense ratios improving as occupancy climbs.